Neoantigen Targeted Therapies Global Market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033

The Business Research Company has updated its global market reports with latest data for 2024 and projections up to 2033

LONDON, GREATER LONDON, UK, July 8, 2024 /EINPresswire.com/ -- The neoantigen targeted therapies market size has experienced significant growth, escalating from $2.43 billion in 2023 to $3.39 billion in 2024, reflecting a compound annual growth rate (CAGR) of 39.3%. This growth can be attributed to advancements in genomic sequencing, evolution of immunotherapy, understanding of tumor immunology, clinical success of checkpoint inhibitors, and advancements in molecular profiling.

Exponential Growth Forecasted
The market is projected to continue its exponential growth trajectory, reaching $11.69 billion by 2028, with a CAGR of 36.3%. This forecasted growth is driven by advancements in bioinformatics, expansion of precision medicine, development of neoantigen vaccines, therapeutic combination strategies, and validation of biomarkers. Major trends in this period include management of neoantigen resistance, adoption of neoantigen-primed adoptive cell therapies, development of neoantigen-based combinatorial therapies, integration of real-world data, and enhanced predictive models.

Explore comprehensive insights into the global neoantigen targeted therapies market with a detailed sample report: https://www.thebusinessresearchcompany.com/report/neoantigen-targeted-therapies-global-market-report

Increasing Incidence of Cancer Cases Driving Market Growth
The increasing incidence of cancer cases globally is a key factor propelling the growth of the neoantigen targeted therapies market. According to the American Cancer Society, in 2022, the United States alone witnessed 1.9 million new cancer cases and approximately 609,360 cancer-related deaths. This underscores the urgent need for effective cancer treatments like neoantigen targeted therapies, which are increasingly used in combination to treat various types of cancer.

Key Players and Market Dynamics
Major companies driving innovation in the neoantigen targeted therapies market include F. Hoffmann-La Roche AG, Merck and Co. Inc., Bristol Myers Squibb Company, GlaxoSmithKline PLC, and others. These companies are leveraging strategic partnerships to personalize neoantigen vaccines and monoclonal antibody drugs, aiming to overcome challenges in existing immunotherapy for solid tumors. For example, Innovent Biologics partnered with NeoCura Bio-Medical Technology Co. Ltd. to evaluate combination therapies using sintilimab and NEO_PLIN2101 for cancer treatment in China.

Market Segments
The neoantigen targeted therapies market is segmented based on:
• Type: Monotherapy, Combination Therapy
• Immunotherapy Type: DNA Or RNA-Based Vaccines, Protein-Based Vaccines, Dendritic Cell Vaccines, TIL-Based Therapies
• Target Disease Indication: Colorectal Cancer, Renal Cell Carcinoma, Non-Small Cell Lung Cancer, Bone Cancer, Gynecological Cancer
• Route of Administration: Intradermal, Intravenous, Subcutaneous
• Application: Medical Research Institution, Hospital and Clinic, Other Applications

Regional Insights
North America led the neoantigen targeted therapies market in 2023 and is expected to maintain significant growth. The market report covers regional dynamics across Asia-Pacific, Western Europe, Eastern Europe, South America, Middle East, and Africa, providing insights into market trends and growth opportunities.

Access the Complete Report
Explore the report store to make a direct purchase of the report https://www.thebusinessresearchcompany.com/report/neoantigen-targeted-therapies-global-market-report

Neoantigen Targeted Therapies Global Market Report 2024 from TBRC covers the following information:
• Market size data for the forecast period: Historical and Future
• Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
• Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.
The Neoantigen Targeted Therapies Global Market Report 2024 by The Business Research Company is the most comprehensive report that provides insights on neoantigen targeted therapies market size, neoantigen targeted therapies market drivers and trends, neoantigen targeted therapies market major players, competitors' revenues, market positioning, and market growth across geographies. The neoantigen targeted therapies market report helps you gain in-depth insights on opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company:

Pain Management Devices And Therapies Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/pain-management-devices-and-therapies-global-market-report

Heart Pump Devices Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/heart-pump-devices-global-market-report

Quit Smoking Drugs Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/quit-smoking-drugs-global-market-report

About The Business Research Company
The Business Research Company has published over 27 industries, spanning over 8000+ markets and 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database
The Global Market Model, The Business Research Company’s flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
X
LinkedIn

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.